$0.92
1.02%
Nasdaq, Nov 14, 10:00 pm CET
ISIN
US95075A1079
Symbol
HOWL

Werewolf Therapeutics Inc Stock price

$0.92
-0.75 45.02% 1M
-0.07 7.25% 6M
-0.56 37.96% YTD
-1.01 52.42% 1Y
-1.30 58.64% 3Y
-15.18 94.30% 5Y
-15.18 94.30% 10Y
-15.18 94.30% 20Y
Nasdaq, Closing price Fri, Nov 14 2025
-0.01 1.02%
ISIN
US95075A1079
Symbol
HOWL
Industry

Key metrics

Basic
Market capitalization
$44.6m
Enterprise Value
$6.5m
Net debt
positive
Cash
$65.7m
Shares outstanding
47.3m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | -
EV/Sales
- | -
EV/FCF
negative
P/B
1.5
Financial Health
Equity Ratio
57.8%
Return on Equity
-96.1%
ROCE
-115.4%
ROIC
-
Debt/Equity
0.9
Financials (TTM | estimate)
Revenue
$0.0 | $0.0
EBITDA
$-69.9m | $-72.0m
EBIT
$-71.6m | $-73.8m
Net Income
$-72.8m | $-75.2m
Free Cash Flow
$-63.6m
Growth (TTM | estimate)
Revenue
-100.0% | -100.0%
EBITDA
-8.6% | -0.3%
EBIT
-8.2% | -0.2%
Net Income
-17.3% | -6.7%
Free Cash Flow
-35.8%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
$-1.6
FCF per Share
$-1.3
Short interest
2.6%
Employees
46
Rev per Employee
$40.0k
Show more

Is Werewolf Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,042 stocks worldwide.

Werewolf Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

12 Analysts have issued a Werewolf Therapeutics Inc forecast:

11x Buy
92%
1x Hold
8%

Analyst Opinions

12 Analysts have issued a Werewolf Therapeutics Inc forecast:

Buy
92%
Hold
8%

Financial data from Werewolf Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 18 18
7% 7%
-
- Research and Development Expense 54 54
6% 6%
-
-70 -70
9% 9%
-
- Depreciation and Amortization 1.68 1.68
9% 9%
-
EBIT (Operating Income) EBIT -72 -72
8% 8%
-
Net Profit -73 -73
17% 17%
-

In millions USD.

Don't miss a Thing! We will send you all news about Werewolf Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Werewolf Therapeutics Inc Stock News

Neutral
GlobeNewsWire
10 days ago
Novel INDUCER™ T Cell Engager Platform designed to mitigate systemic toxicities Sequential dosing of INDUKINE™ molecules in preclinical model showed potent antitumor activity with improved safety First-in-kind real-time pharmacokinetic data in a mouse tumor model confirmed WTX-124 selective activation in tumors, sparing healthy tissue WATERTOWN, Mass., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Werewolf...
Neutral
GlobeNewsWire
13 days ago
– Update on WTX-124 Phase 1/1b clinical trial interim data and End of Phase 1 meeting with the U.S. Food & Drug Administration (FDA) is expected to be provided later in the fourth quarter of 2025 – – Update on Phase 1b/2 clinical trial of WTX-330 and potential further development plan is expected to be provided later in the fourth quarter of 2025 – – WTX-1011, Company's first INDUCER™   T-cell ...
Neutral
GlobeNewsWire
about one month ago
Fast Track Designation underscores the promise of Werewolf's INDUKINE™ platform WATERTOWN, Mass., Oct. 08, 2025 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer and other immune-mediated conditions, today announced that the Company ...
More Werewolf Therapeutics Inc News

Company Profile

Werewolf Therapeutics, Inc. is a biopharmaceutical company. It engages in the development of of therapeutics engineered to stimulate the body’s immune system for the treatment of cancer. The firm offers Predator Technology which focuses on immune targeting and activation. The company was founded by Daniel J. Hicklin, Patrick A. Baeuerle, and Luke B. Evnin on October 19, 2017 and is headquartered in Cambridge, MA.

Head office United States
CEO Dan Hicklin
Employees 46
Founded 2017
Website werewolftx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today